Search

everythinglearnresearchcommunity

for

Search:↓

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.

JAK inhibitors show promise for treating Alopecia Areata, but more research is needed for better, accessible treatments.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tofacitinib may help regrow hair in alopecia areata patients.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Topical Ruxolitinib may safely treat severe hair loss.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.